- HOME
- Laboratories
- Molecular Biotherapy
- Publications
- Original articles
Update :
2024/08/26
Contents
Original articles
2024|2023|2022|2021|2020|2019|2018|2017|2016|2015|2014|2013|2012|2011|2010|2009|2008|2007|2006|2005
2024年
- Suenaga M, Mashima T, Kawata N, Dan S, Seimiya H, Yamaguchi K.
- Exploratory study identifies matrix metalloproteinase-14 and -9 as potential biomarkers of regorafenib efficacy in metastatic colorectal cancer. Cancers. 16: 2855 (2024)
- Yanagiya R, Miyatake Y, Watanabe N, Shimizu T, Kanamori A, Ueno M, Okabe S, Carreras J, Nakayama S, Hasegawa A, Kameda K, Kamakura T, Nakagawa S, Yamauchi T, Maeda T, Ishii K, Matsuura T, Handa H, Hirao A, Ishizawa K, Onizuka M, Mashima T, Nakamura N, Ando K, Kotani A.
- Amino acid influx via LAT1 regulates iron demand and sensitivity to PPMX-T003 of aggressive natural killer cell leukemia. Leukemia. 38: 1731-1741 (2024)
- Nakamura A, Mashima T, Lee J, Inaba S, Kawata N, Morino S, Kumagai K, Yamaguchi K, Seimiya H.
- Intratumor transforming growth factor-β signaling with extracellular matrix-related gene regulation marks chemotherapy-resistant gastric cancer. Biochem Biophys Res Commun. 721: 150108 (2024)
- Lee J, Mashima T, Kawata N, Yamamoto N, Morino S, Inaba S, Nakamura A, Kumagai K, Wakatsuki T, Takeuchi K, Yamaguchi K, Seimiya H.
- Pharmacological targeting of histone H3K27 acetylation/BRD4-dependent induction of ALDH1A3 for early-phase drug tolerance of gastric cancer. Cancer Res Commun. 4: 1307-1320 (2024).
- Morino S, Mashima T, Shirai F, Nagayama S, Katayama R, Seimiya H.
- BET protein-dependent E2F pathway activity confers bell-shaped type resistance to tankyrase inhibitors in APC-mutated colorectal cancer. Cancer Lett. 584: 216632 (2024)
- Hirose S, Mashima T, Yuan X, Yamashita M, Kitano S, Torii S, Migita T, Seimiya H.
- Interleukin-4 induced 1-mediated resistance to an immune checkpoint inhibitor through suppression of CD8(+) T cell infiltration in melanoma. Cancer Sci. 115: 791-803 (2024)
- Chen M*, Mashima T*, Oishi T*, Muramatsu Y, Seto Y, Takamatsu M, Kawata N, Morino S, Nakamura A, Inaba S, Yuan X, Maruyama K, Suzuki M, Sato A, Yoshida H, Jang MK, Mizutani A, Takeuchi K, Yamaguchi K, Shirai F, Nagayama S, Katayama R, Seimiya H.
- APC/PIK3CA mutations and β-catenin status predict tankyrase inhibitor sensitivity of patient-derived colorectal cancer cells. Br J Cancer. 130: 151-162 (2024). *Equally contributed.
2023年
- Mezawa Y, Wang T, Daigo Y, Takano A, Miyagi Y, Yokose T, Yamashita T, Yang L, Maruyama R, Seimiya H, Orimo A.
- Glutamine deficiency drives transforming growth factor-β signaling activation that gives rise to myofibroblastic carcinoma-associated fibroblasts. Cancer Sci. 114: 4376-4387 (2023)
- Chiba M, Miyata K, Okawa H, Tanaka Y, Ueda K, Seimiya H, Takahashi A.
- YBX1 Regulates Satellite II RNA Loading into Small Extracellular Vesicles and Promotes the Senescent Phenotype. Int J Mol Sci. 24: (2023)
2022年
- Moyret-Lalle C, Prodhomme MK, Burlet D, Kashiwagi A, Petrilli V, Puisieux A, Seimiya H*, Tissier A*.
- Role of EMT in the DNA damage response, double-strand break repair pathway choice and its implications in cancer treatment. Cancer Sci. 113: 2214-2223 (2022). *Equally contributed.
2021年
- Seimiya H, Nagasawa K, Shin-Ya K.
- Chemical targeting of G-quadruplexes in telomeres and beyond for molecular cancer therapeutics. J Antibiot (Tokyo). 74: 617-628 (2021)
- Nishiya N, Oku Y, Ishikawa C, Fukuda T, Dan S, Mashima T, Ushijima M, Furukawa Y, Sasaki Y, Otsu K, Sakyo T, Abe M, Yonezawa H, Ishibashi F, Matsuura M, Tomida A, Seimiya H, Yamori T, Iwao M, Uehara Y.
- Lamellarin 14, a derivative of marine alkaloids, inhibits the T790M/C797S mutant epidermal growth factor receptor. Cancer Sci. 112: 1963-1974 (2021)
- Matsumoto K, Okamoto K, Okabe S, Fujii R, Ueda K, Ohashi K, Seimiya H.
- G-quadruplex-forming nucleic acids interact with splicing factor 3B subunit 2 and suppress innate immune gene expression. Genes Cells. 26: 65-82 (2021)
- Tanji K, Mori F, Shirai F, Fukami T, Seimiya H, Utsumi J, Kakita A, Wakabayashi K.
- Novel tankyrase inhibitors suppress TDP-43 aggregate formation. Biochem Biophys Res Commun. 537: 85-92 (2021)
- Suenaga M, Mashima T, Kawata N, Wakatsuki T, Dan S, Seimiya H, Yamaguchi K.
- Serum IL-8 level as a candidate prognostic marker of response to anti-angiogenic therapy for metastatic colorectal cancer. Int J Colorectal Dis. 36: 131-139 (2021)
- Shimizu T, Takahashi N, Huber VJ, Asawa Y, Ueda H, Yoshimori A, Muramatsu Y, Seimiya H, Kouji H, Nakamura H, Oguri H.
- Design and synthesis of 14 and 15-membered macrocyclic scaffolds exhibiting inhibitory activities of hypoxia-inducible factor 1α. Bioorg Med Chem. 30: 115949 (2021)
- Miyata K, Imai Y, Hori S, Nishio M, Loo TM, Okada R, Yang L, Nakadai T, Maruyama R, Fujii R, Ueda K, Jiang L, Zheng H, Toyokuni S, Sakata T, Shirahige K, Kojima R, Nakayama M, Oshima M, Nagayama S, Seimiya H, Hirota T, Saya H, Hara E, Takahashi A.
- Pericentromeric noncoding RNA changes DNA binding of CTCF and inflammatory gene expression in senescence and cancer. Proc Natl Acad Sci U S A. 118: (2021)
- Mashima T, Wakatsuki T, Kawata N, Jang MK, Nagamori A, Yoshida H, Nakamura K, Migita T, Seimiya H, Yamaguchi K. Neutralization of the induced VEGF-A potentiates the therapeutic effect of an anti-VEGFR2 antibody on gastric cancer in vivo. Sci Rep. 11: 15125 (2021)
2020年
- Yasuda M, Ma Y, Okabe S, Wakabayashi Y, Su D, Chang YT, Seimiya H, Tera M, Nagasawa K.
- Target identification of a macrocyclic hexaoxazole G-quadruplex ligand using post-target-binding visualization. Chem Commun (Camb). 56: 12905-12908 (2020)
- Seimiya H.
- Crossroads of telomere biology and anticancer drug discovery. Cancer Sci. in press
- Koi H, Takahashi N, Fuchi Y, Umeno T, Muramatsu Y, Seimiya H, Karasawa S, Oguri H.
- A fully synthetic 6-aza-artemisinin bearing an amphiphilic chain generates aggregates and exhibits anti-cancer activities. Org Biomol Chem. 18: 5339-5343 (2020)
- Nakanishi C, Seimiya H.
- G-quadruplex in cancer biology and drug discovery. Biochem Biophys Res Commun. in press
- Jang MK, Mashima T, Seimiya, H.
- Tankyrase inhibitors target colorectal cancer stem cells via AXIN-dependent downregulation of c-KIT tyrosine kinase. Mol Cancer Ther. 19: 765-776 (2020)
- Kawakami R, Mashima T, Kawata N, Kumagai K, Migita T, Sano T, Mizunuma N, Yamaguchi K, Seimiya H.
- ALDH1A3-mTOR axis as a therapeutic target for anticancer drug-tolerant persister cells in gastric cancer. Cancer Sci. 111: 962-973 (2020)
- Tomizawa F, Jang MK, Mashima T, Seimiya H.
- c-KIT regulates stability of cancer stemness in CD44-positive colorectal cancer cells. Biochem Biophys Res Commun. 527: 1014-1020 (2020)
- Shirai F, Mizutani A, Yashiroda Y, Tsumura T, Kano Y, Muramatsu Y, Chikada T, Yuki H, Niwa H, Sato S, Washizuka K, Koda Y, Mazaki Y, Jang MK, Yoshida H, Nagamori A, Okue M, Watanabe T, Kitamura K, Shitara E, Honma T, Umehara T, Shirouzu M, Fukami T, Seimiya H, Yoshida M, Koyama H.
- Design and discovery of an orally efficacious spiroindolinone-based tankyrase inhibitor for the treatment of colon cancer. J Med Chem. 63: 4183-4204 (2020)
- Matsusaka S, Hanna DL, Ning Y, Yang D, Cao S, Berger MD, Miyamoto Y, Suenaga M, Dan S, Mashima T, Seimiya H, Zhang W, Lenz HJ.
- Epidermal growth factor receptor mRNA expression: A potential molecular escape mechanism from regorafenib. Cancer Sci. 111: 441-450 (2020)
- Mizutani A, Seimiya H.
- Tankyrase promotes primary precursor miRNA processing to precursor miRNA. Biochem Biophys Res Commun. 522: 945-951 (2020)
- Suenaga M, Wakatsuki T, Mashima T, Ogura M, Ichimura T, Shinozaki E, Nakayama I, Osumi H, Ota Y, Takahari D, Chin K, Seimiya H, Yamaguchi K.
- A phase I study to determine the maximum tolerated dose of trifluridine/tipiracil and oxaliplatin in patients with refractory metastatic colorectal cancer: LUPIN study. Invest New Drugs 38: 111-119 (2020)
2019
- Okamoto K, Seimiya H.
-
From the wings to the center stage of chromosomes.
J Biol Chem., 294: 17723-17724 (2019) - Mashima T, Iwasaki R, Kawata N, Kawakami R, Kumagai K, Migita T, Sano T, Yamaguchi K, Seimiya H.
- In silico chemical screening identifies epidermal growth factor receptor as a therapeutic target of drug-tolerant CD44v9-positive gastric cancer cells. Br J Cancer. 121: 846-856 (2019)
- Shirai F, Tsumura T, Yashiroda Y, Yuki H, Niwa H, Sato S, Chikada T, Koda Y, Washizuka K, Yoshimoto N, Abe M, Onuki T, Mazaki Y, Hirama C, Fukami T, Watanabe H, Honma T, Umehara T, Shirouzu M, Okue M, Kano Y, Watanabe T, Kitamura K, Shitara E, Muramatsu Y, Yoshida H, Mizutani A, Seimiya H, Yoshida M, Koyama H.
-
Discovery of novel spiroindoline derivatives as selective tankyrase inhibitors.
J Med Chem. 62: 3407-3427 (2019) - Okamoto K, Seimiya H.
- Revisiting Telomere Shortening in Cancer. Cells. 8: E107 (2019)
2018
- Okamoto, K., Ohishi, T., Kuroiwa, M., Iemura, S., Natsume, T., Seimiya, H.
- MERIT40-dependent recruitment of tankyrase to damaged DNA and its implication for cell sensitivity to DNA-damaging anticancer drugs. Oncotarget, 9: 35844-35855 (2018)
- Hatta, T., Iemura, S. I., Ohishi, T., Nakayama, H., Seimiya, H., Yasuda, T., Iizuka, K., Fukuda, M., Takeda, J., Natsume, T., Horikawa, Y.
- Calpain-10 regulates actin dynamics by proteolysis of microtubule-associated protein 1B. Scientific Reports, 8: 16756 (2018)
- Mizutani, A., Yashiroda, Y., Muramatsu, Y., Yoshida, H., Chikada, T., Tsumura, T., Okue, M., Shirai, F., Fukami, T., Yoshida, M., Seimiya, H.
- RK-287107, a potent and specific tankyrase inhibitor, blocks colorectal cancer cell growth in a preclinical model. Cancer Science, 109: 4003-4014 (2018), Issue Highlight
- Fujiwara, C., Muramatsu, Y., Nishii, M., Tokunaka, K., Tahara, H., Ueno, M., Yamori, T., Sugimoto, Y., Seimiya, H.
- Cell-based chemical fingerprinting identifies telomeres and lamin A as modifiers of DNA damage response in cancer cells. Scientific Reports, 8: 14827 (2018)
- Ma, Y., Tsushima, Y., Sakuma, M., Sasaki, S., Iida, K., Okabe, S., Seimiya, H., Hirokawa, T., Nagasawa, K.
- Development of G-quadruplex ligands for selective induction of a parallel-type topology. Organic & Biomolecular Chemistry, 16: 7375-7382 (2018)
- Suenaga, M., Schirripa, M., Cao, S., Zhang, W., Yang, D., Ning, Y., Cremolini, C., Antoniotti, C., Borelli, B., Mashima, T., Okazaki, S., Berger, M. D., Miyamoto, Y., Gopez, R., Jr., Barzi, A., Lonardi, S., Yamaguchi, T., Falcone, A., Loupakis, F., Lenz, H. J.
- Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib. Clinical Colorectal Cancer, 17: e395-e414 (2018)
- Osumi, H., Shinozaki, E., Mashima, T., Wakatsuki, T., Suenaga, M., Ichimura, T., Ogura, M., Ota, Y., Nakayama, I., Takahari, D., Chin, K., Miki, Y., Yamaguchi, K.
- Phase II trial of biweekly cetuximab and irinotecan as third-line therapy for pretreated KRAS exon 2 wild-type colorectal cancer. Cancer Science, 109: 2567-2575 (2018)
2017
- T. Nakamura, S. Okabe, H. Yoshida, K. Iida, Y. Ma, S. Sasaki, T. Yamori, K. Shin-ya, I. Nakano, K. Nagasawa, H. Seimiya.
- Targeting glioma stem cells in vivo by a G-quadruplex-stabilizing synthetic macrocyclic hexaoxazole. Sci Rep, 7: 3605 (2017)
- T. Mashima, Y Taneda, M.K. Jang, A. Mizutani, Y. Muramatsu, H. Yoshida, A. Sato, N. Tanaka, Y. Sugimoto, H. Seimiya.
- mTOR signaling mediates resistance to tankyrase inhibitors in Wnt-driven colorectal cancer. Oncotarget, in press (2017)
- T. Migita, A. Ueda, T. Ohishi, M. Hatano, H. Seimiya, S. Horiguchi, F. Koga and F. Shibasaki.
- Epithelial-mesenchymal transition promotes SOX2 and NANOG expression in bladder cancer. Lab Invest, 97: 567-576 (2017)
- T. Ohishi, H. Yoshida, M. Katori, T. Migita, Y. Muramatsu, M. Miyake, Y. Ishikawa, A. Saiura, S. Iemura, T. Natsume and H. Seimiya.
- Tankyrase-binding protein TNKS1BP1 regulates actin cytoskeleton rearrangement and cancer cell invasion.
Cancer Res, 77: 2328-2338 (2017) - N. Tanaka, T. Mashima, A. Mizutani, A. Sato, A. Aoyama, B. Gong, H. Yoshida, Y. Muramatsu, K. Nakata, M. Matsuura, R. Katayama, S. Nagayama, N. Fujita, Y. Sugimoto and H. Seimiya.
- APC mutations as a potential biomarker for sensitivity to tankyrase inhibitors in colorectal cancer. Mol Cancer Ther, 16, 752-762 (2017)
2016
- D. Hasegawa, S. Okabe, K. Okamoto, I. Nakano, K. Shin-Ya and H. Seimiya.
- G-quadruplex ligand-induced DNA damage response coupled with telomere dysfunction and replication stress in glioma stem cells.
Biochemical and biophysical research communications, 471, 75-81 (2016) - Y. Hayakawa, M. Kawada, H. Nishikawa, T. Ochiya, H. Saya, H. Seimiya, R. Yao, M. Hayashi, C. Kai, A. Matsuda, T. Naoe, A. Ohtsu, T. Okazaki, H. Saji, M. Sata, H. Sugimura, Y. Sugiyama, M. Toi and T. Irimura.
- Report on the use of non-clinical studies in the regulatory evaluation of oncology drugs.
Cancer science, 107, 189-202 (2016) - A. Mizutani, D. Koinuma, H. Seimiya and K. Miyazono.
- The Arkadia-ESRP2 axis suppresses tumor progression: analyses in clear-cell renal cell carcinoma.
Oncogene, 35, 3514-23 (2016) - T. Nakamura, Y. Ma, K. Iida, T. Ohtake, H. Seimiya and K. Nagasawa.
- Design, synthesis and evaluation of an L-Dopa-derived macrocyclic hexaoxazole (6OTD) as a G-quadruplex-selective ligand.
Heterocycles, 92, 305-315 (2016) - R. Ouchi, S. Okabe, T. Migita, I. Nakano and H. Seimiya.
- Senescence from glioma stem cell differentiation promotes tumor growth.
Biochemical and biophysical research communications, 470, 275-81 (2016) - M. Suenaga, T. Mashima, N. Kawata, T. Wakatsuki, Y. Horiike, S. Matsusaka, S. Dan, E. Shinozaki, H. Seimiya, N. Mizunuma, K. Yamaguchi and T. Yamaguch.
- Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer.
Oncotarget, 7, 34811-23 (2016)
2015
- K. Hirashima and H. Seimiya.
- Telomeric repeat-containing RNA/G-quadruplex-forming sequences cause genome-wide alteration of gene expression in human cancer cells in vivo.
Nucleic acids research, 43, 2022-32 (2015) - T. Mashima, M. Ushijima, M. Matsuura, S. Tsukahara, K. Kunimasa, A. Furuno, S. Saito, M. Kitamura, T. Soma-Nagae, H. Seimiya, S. Dan, T. Yamori and A. Tomida.
- Comprehensive transcriptomic analysis of molecularly targeted drugs in cancer for target pathway evaluation.
Cancer Science, 106, 909-20 (2015) - H. Seimiya.
- Predicting Risk at the End of the End: Telomere G-tail as a Biomarker.
EBioMedicine, 2, 802-3 (2015) - M. Tera, T. Hirokawa, S. Okabe, K. Sugahara, H. Seimiya and K. Shimamoto.
- Design and synthesis of a berberine dimer: A fluorescent ligand with high affinity towards G-quadruplexes.
Chemistry, 21, 14519-28 (2015)
2014
- Mashima, T., Soma-Nagae, T., Migita, T., Kinoshita, R., Iwamoto, A., Yuasa, T., Yonese, J., Ishikawa, Y., Seimiya, H.
- TRIB1 supports prostate tumorigenesis and tumor-propagating cell survival by regulation of endoplasmic reticulum chaperone expression. Cancer Res. 74, 4888-4897 (2014)
- Shimamoto A, Kagawa H, Zensho K, Sera Y, Kazuki Y, Osaki M, Oshimura M, Ishigaki Y, Hamasaki K, Kodama Y, Yuasa S, Fukuda K, Hirashima K, Seimiya H, Koyama H, Shimizu T, Takemoto M, Yokote K, Goto M, Tahara H.
- Reprogramming suppresses premature senescence phenotypes of Werner syndrome cells and maintains chromosomal stability over long-term culture. PLoS One. 9, e112900 (2014)
- Migita, T., Okabe, S., Ikeda, K., Igarashi, S., Sugawara, S., Tomida, A., Soga, T., Taguchi, R., Seimiya, H.
- Inhibition of ATP citrate lyase induces triglyceride accumulation with altered fatty acid composition in cancer cells.
Int J Cancer, 135, 37-47 (2014) - Ohishi, T., Muramatsu, Y., Yoshida, H., Seimiya, H.
- TRF1 ensures the centromeric function of Aurora-B and proper chromosome segregation.
Mol Cell Biol, 34, 2464-2478 (2014)
2013
- Hirashima, K., Migita, T., Sato, S., Muramatsu, Y., Ishikawa, Y., Seimiya, H.
- Telomere length influences cancer cell differentiation in vivo.
Mol Cell Biol, 33, 2988-2995 (2013) - Iida, K., Majima, S., Nakamura, T., Seimiya, H., Nagasawa, K.
- Evaluation of the interaction between long telomeric DNA and macrocyclic hexaoxazole (6OTD) dimer of a G-quadruplex ligand.
Molecules, 18, 4328-4341 (2013) - Migita, T., Okabe, S., Ikeda, K., Igarashi, S., Sugawara, S., Tomida, A., Taguchi, R., Soga, T., Seimiya, H.
- Inhibition of ATP citrate lyase induces an anticancer effect via reactive oxygen species: AMPK as a predictive biomarker for therapeutic impact.
Am J Pathol, 182, 1800-1820 (2013) - Ushijima, M., Mashima, T., Tomida, A., Dan, S., Saito, S., Furuno, A., Tsukahara, S., Seimiya, H., Yamori, T., Matsuura, M.
- Development of a gene expression database and related analysis programs for evaluation of anticancer compounds.
Cancer Sci, 104, 360-368 (2013)
2012
- Deardorff, M.A., Bando, M., Nakato, R., Watrin, E., Itoh, T., Minamino, M., Saitoh, K., Komata, M., Katou, Y., Clark, D., Cole, K.E., De Baere, E., Decroos, C., Di Donato, N., Ernst, S., Francey, L.J., Gyftodimou, Y., Hirashima, K., Hullings, M., Ishikawa, Y., Jaulin, C., Kaur, M., Kiyono, T., Lombardi, P.M., Magnaghi-Jaulin, L., Mortier, G.R., Nozaki, N., Petersen, M.B., Seimiya, H., Siu, V.M., Suzuki, Y., Takagaki, K., Wilde, J.J., Willems, P.J., Prigent, C., Gillessen-Kaesbach, G., Christianson, D.W., Kaiser, F.J., Jackson, L.G., Hirota, T., Krantz, I.D., Shirahige, K.
- HDAC8 mutations in Cornelia de Lange syndrome affect the cohesin acetylation cycle.
Nature, 489, 313-317 (2012) - Ha, G.H., Kim, H.S., Go, H., Lee, H., Seimiya, H., Chung, D.H., Lee, C.W.
- Tankyrase-1 function at telomeres and during mitosis is regulated by Polo-like kinase-1-mediated phosphorylation.
Cell Death Differ, 19, 321-332 (2012) - Kawahara, T., Hosoya, T., Tsukamoto, M., Okabe, S., Yamamura, H., Hayakawa, M., Seimiya, H., Takagi, M., Shin-Ya, K.
- JBIR-120: a new growth inhibitor of hormone-refractory prostate cancer cells.
J Antibiot, 65, 373-375 (2012) - Miyazaki, T., Pan, Y., Joshi, K., Purohit, D., Hu, B., Demir, H., Mazumder, S., Okabe, S., Yamori, T., Viapiano, M., Shin-ya, K., Seimiya, H., Nakano, I.
- Telomestatin impairs glioma stem cell survival and growth through the disruption of telomeric G-quadruplex and inhibition of the proto-oncogene, c-Myb.
Clin Cancer Res, 18, 1268-1280 (2012) - Nakamura, T., Iida, K., Tera, M., Shin-Ya, K., Seimiya, H., Nagasawa, K.
- A caged ligand for a telomeric g-quadruplex.
Chembiochem, 13, 774-777 (2012)
2011
- Mashima, T., Okabe, S., Seimiya, H.
- Molecular pharmacological approach reveals potential new strategies to suppress androgen receptor signaling in prostate cancer.
Mol Cell Pharmacol, 3, 7-12 (2011) - Mashima, T., Seimiya, H.
- Role of acyl-CoA synthetases in glioma cell survival and its therapeutic implication.
In Tumors of the central nervous system, Hayat, M.A.e., (Heidelberg, Springer,), 337-340 (2011) - Takahashi, K., Imano, R., Kibe, T., Seimiya, H., Muramatsu, Y., Kawabata, N., Tanaka, G., Matsumoto, Y., Hiromoto, T., Koizumi, Y., Nakazawa, N., Yanagida, M., Yukawa, M., Tsuchiya, E., Ueno, M.
- Fission yeast pot1 and recQ helicase are required for efficient chromosome segregation.
Mol Cell Biol, 31, 495-506 (2011)
2010
- Hatsugai, K., Ohishi, T., Sugimoto, Y., Seimiya, H.
- Tankyrase-1 assembly to large protein complexes blocks its telomeric function.
FEBS Lett, 584, 3885-3890 (2010) - Kobayashi, Y., Sato, K., Kibe, T., Seimiya, H., Nakamura, A., Yukawa, M., Tsuchiya, E., Ueno, M.
- Expression of mutant RPA in human cancer cells causes telomere shortening.
Biosci Biotechnol Biochem, 74, 382-385 (2010) - Mashima, T., Okabe, S., Seimiya, H.
- Pharmacological targeting of constitutively active truncated androgen receptor by nigericin and suppression of hormone-refractory prostate cancer cell growth.
Mol Pharmacol, 78, 846-854 (2010) - Migita, T., Narita, T., Asaka, R., Miyagi, E., Nagano, H., Nomura, K., Matsuura, M., Satoh, Y., Okumura, S., Nakagawa, K., Seimiya, H., Ishikawa, Y.
- Role of insulin-like growth factor binding protein 2 in lung adenocarcinoma: IGF-independent antiapoptotic effect via caspase-3.
Am J Pathol, 176, 1756-1766 (2010) - Ohishi, T., Hirota, T., Tsuruo, T., Seimiya, H.
- TRF1 mediates mitotic abnormalities induced by Aurora-A overexpression.
Cancer Res, 70, 2041-2052 (2010) - Seki, T., Yuasa, S., Oda, M., Egashira, T., Yae, K., Kusumoto, D., Nakata, H., Tohyama, S., Hashimoto, H., Kodaira, M., Okada, Y., Seimiya, H., Fusaki, N., Hasegawa, M., Fukuda, K.
- Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells.
Cell Stem Cell, 7, 11-14 (2010) - Tera, M., Iida, K., Ikebukuro, K., Seimiya, H., Shin-Ya, K., Nagasawa, K.
- Visualization of G-quadruplexes by using a BODIPY-labeled macrocyclic heptaoxazole.
Org Biomol Chem, 8, 2749-2755 (2010) - Yashiroda, Y., Okamoto, R., Hatsugai, K., Takemoto, Y., Goshima, N., Saito, T., Hamamoto, M., Sugimoto, Y., Osada, H., Seimiya, H., Yoshida, M.
- A novel yeast cell-based screen identifies flavone as a tankyrase inhibitor.
Biochem Biophys Res Commun, 394, 569-573 (2010)
2009
- Mashima, T., Sato, S., Okabe, S., Miyata, S., Matsuura, M., Sugimoto, Y., Tsuruo, T., Seimiya, H.
- Acyl-CoA synthetase as a cancer survival factor: its inhibition enhances the efficacy of etoposide.
Cancer Sci, 100, 1556-1562 (2009) - Mashima, T., Sato, S., Sugimoto, Y., Tsuruo, T., Seimiya, H.
- Promotion of glioma cell survival by acyl-CoA synthetase 5 under extracellular acidosis conditions.
Oncogene, 28, 9-19 (2009) - McCabe, N., Cerone, M.A., Ohishi, T., Seimiya, H., Lord, C.J., Ashworth, A.
- Targeting Tankyrase 1 as a therapeutic strategy for BRCA-associated cancer.
Oncogene, 28, 1465-1470 (2009) - Schulz, R., Vogel, T., Mashima, T., Tsuruo, T., Krieglstein, K.
- Involvement of fractin in TGF-β-induced apoptosis in oligodendroglial progenitor cells.
Glia, 57, 1619-1629 (2009)
2008
- Migita, T., Narita, T., Nomura, K., Miyagi, E., Inazuka, F., Matsuura, M., Ushijima, M., Mashima, T., Seimiya, H., Satoh, Y., Okumura, S., Nakagawa, K., Ishikawa, Y.
- ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer.
Cancer Res, 68, 8547-8554 (2008) - Muramatsu, Y., Tahara, H., Ono, T., Tsuruo, T., Seimiya, H.
- Telomere elongation by a mutant tankyrase 1 without TRF1 poly(ADP-ribosyl)ation.
Exp Cell Res, 314, 1115-1124 (2008) - Yeung, B.H., Wong, K.Y., Lin, M.C., Wong, C.K., Mashima, T., Tsuruo, T., Wong, A.S.
- Chemosensitisation by manganese superoxide dismutase inhibition is caspase-9 dependent and involves extracellular signal-regulated kinase 1/2.
Br J Cancer, 99, 283-293 (2008)
2007
- Muramatsu, Y., Ohishi, T., Sakamoto, M., Tsuruo, T., Seimiya, H.
- Cross-species difference in telomeric function of tankyrase 1.
Cancer Sci, 98, 850-857 (2007) - Ohishi, T., Tsuruo, T., Seimiya, H.
- Evaluation of tankyrase inhibition in whole cells.
Methods Mol Biol, 405, 133-146 (2007) - Tanaka, E., Fukuda, H., Nakashima, K., Tsuchiya, N., Seimiya, H., Nakagama, H.
- HnRNP A3 binds to and protects mammalian telomeric repeats in vitro.
Biochem Biophys Res Commun, 358, 608-614 (2007)
2006
- Kimura, H., Katoh, T., Kajimoto, T., Node, M., Hisaki, M., Sugimoto, Y., Majima, T., Uehara, Y., Yamori, T.
- Modification of pyrimidine derivatives from antiviral agents to antitumor agents.
Anticancer Res, 26, 91-97 (2006) - Tahara, H., Shin-Ya, K., Seimiya, H., Yamada, H., Tsuruo, T., Ide, T.
- G-Quadruplex stabilization by telomestatin induces TRF2 protein dissociation from telomeres and anaphase bridge formation accompanied by loss of the 3' telomeric overhang in cancer cells.
Oncogene, 25, 1955-1966 (2006)
2005
- Seimiya, H., Muramatsu, Y., Ohishi, T., Tsuruo, T.
- Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics.
Cancer Cell, 7, 25-37 (2005)